The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline hydrochloride extended-release capsules, to be used in the treatment ...

The FDA has approved Emrosi for the treatment of rosacea in adults, Journey Medical Corporation announced in a press release. “For many of the millions of patients diagnosed with rosacea ...

TUESDAY, Nov. 12, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Emrosi (minocycline hydrochloride) for the treatment of inflammatory rosacea in adults. The extended ...

Rosacea is estimated to affect around 16 million people in the US, said Journey's chief executive, Claude Maraoui, on an investor call held after the approval was announced, adding that Emrosi is ...

(RTTNews) - Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

Journey Medical Corporation announced that its FDA-approved treatment for rosacea, Emrosi™, was featured in a segment of “The Balancing Act®” aired on Lifetime TV on June 9, 2025, with a ...

The FDA has approved an antibiotic called minocycline for the treatment of rosacea in adults. The drug, which is taken orally, will be sold under the brand name Emrosi.

Emrosi was approved by the FDA in November 2024 and launched by Journey Medical on March 24. ... Dermatology of the phase 3 clinical trial results of Emrosi (DFD-29) to treat rosacea.

The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in adults, drugmaker Journey Medical announced on Monday.. Approval of ...

SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage ...

The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline hydrochloride extended-release capsules, to be used in the treatment ...